Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun 1;41(16):3074-3075.
doi: 10.1200/JCO.23.00072. Epub 2023 Apr 4.

Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma

Timothy A Lin  1 , Ananya Das  1 , Zachary McCaw  1 , Ethan B Ludmir  1
Affiliations
Comment

Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma

Timothy A Lin et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ethan B. Ludmir

Employment: Alaunos Therapeutics (I)

No other potential conflicts of interest were reported.

Comment in

  • Reply to T.A. Lin et al.
    Qin S. Qin S. J Clin Oncol. 2023 Jun 1;41(16):3075. doi: 10.1200/JCO.23.00482. Epub 2023 Apr 4. J Clin Oncol. 2023. PMID: 37015028 No abstract available.

Comment on

References

    1. Qin S, Chen Z, Fang W, et al. : Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial. J Clin Oncol 41:1434-1443, 2023 - PMC - PubMed
    1. Uno H, Claggett B, Tian L, et al. : Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32:2380-2385, 2014 - PMC - PubMed
    1. Guyot P, Ades AE, Ouwens MJNM, et al. : Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9, 2012 - PMC - PubMed
    1. Pak K, Uno H, Kim DH, et al. : Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. JAMA Oncol 3:1692-1696, 2017 - PMC - PubMed

MeSH terms

Substances